Rallybio
RLYB
47 hedge funds and large institutions have $194M invested in Rallybio in 2022 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 16 increasing their positions, 8 reducing their positions, and 2 closing their positions.
450% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 8
28% more capital inflows, than outflows
Capital inflows: $19.6M | Capital outflows: $15.3M
24% more funds holding
Funds holding: 38 → 47 (+9)
1.08% more ownership
Funds ownership: 85.37% → 86.45% (+1.1%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Novo Holdings A/S
Hellerup,
Denmark
|
+$4.51M |
| 2 |
BlackRock
New York
|
+$4.41M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.04M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.09M |
| 5 |
State Street
Boston,
Massachusetts
|
+$876K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$8.62M |
| 2 |
JP Morgan Chase
New York
|
-$3.27M |
| 3 |
5AM Venture Management
San Francisco,
California
|
-$2.17M |
| 4 |
Tekla Capital Management
Boston,
Massachusetts
|
-$1.18M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$26K |
RLYB Hedge Fund Activity: Q1 2022 in Review
47 of the 6,365 institutional investors tracked by Wall St. Rank reported a position in Rallybio (RLYB) for Q1 2022, worth a combined $194M — down 25% from $260M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new RLYB positions and 2 closed out — a net gain of 9 holders — while 16 added to existing stakes and 8 trimmed.
The largest buyer was Novo Holdings A/S, opening a new position worth an estimated $4.51M. The largest seller was HHLR Advisors, exiting entirely with an estimated $8.62M sold.
- 47 institutional investors held Rallybio (RLYB) as of Q1 2022, up from 38 in Q4 2021.
- Funds reported $194M of Rallybio stock for Q1 2022, down 25% quarter-over-quarter.
- 11 funds opened new Rallybio positions in Q1 2022 and 2 closed out, a net change of +9 holders.
- The largest Rallybio buyer in Q1 2022 was Novo Holdings A/S, an estimated $4.51M added.
- The largest Rallybio seller in Q1 2022 was HHLR Advisors, an estimated $8.62M sold.
Based on aggregated 13F filings for Q1 2022.